treatment of pulmonary arterial hypertension
All entries for: Inhibikase Therapeutics, Inc.
July 16, 2026
Inhibikase Therapeutics, Inc.
Orphan Drug Designation
Wilmington, DE
1-50 employees
Disease Area: Rare Diseases
March 26, 2026
Inhibikase Therapeutics, Inc.
Neutral Outlook
Wilmington, DE
1-50 employees
On May 12, 2025, President Trump signed an executive order directing the Secretary of HHS to set and communicate most-favored-nation (“MFN”) price targets to manufacturers and propose a rulemaking plan to impose MFN pricing if “significant progress” is not made, and also directing the federal government to support regulatory paths to allow direct-to-patient sales for companies that meet these targets. The executive order further states that the Administration will take additional action (for example, examining whether marketing approvals should be modified or rescinded or considering individual drug importation waiver authorities) should manufacturers fail to offer American consumers the MFN lowest price.